Literature DB >> 19165625

Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer.

Kristen M Drescher1, Poonam Sharma, Patrice Watson, Zoran Gatalica, Stephen N Thibodeau, Henry T Lynch.   

Abstract

The ability of the host to mount an appropriate immune response to aberrant cells is one factor that determines prognosis in cancer patients. Naturally occurring regulatory T cells (T regs; CD4+ CD25+ cells) are key regulators of peripheral tolerance. It has been suggested that high levels of T regs are detrimental to the patient in some forms of cancer, but the role of these antigen-specific cells in individuals with colorectal cancers with high levels of microsatellite instability is unknown. Herein, we examined the ability of individuals with MSI-H or microsatellite stable colon cancer to recruit lymphocytes to the tumor site. Immunohistochemical staining was performed on archived paraffin-embedded specimens from a total of 38 individuals with MSI-H (n = 25) or MSS (n = 13) colon cancers to determine the proportion of CD3+, CD8+ and CD25+ cells infiltrating the tumor site. Patients with MSI-H colon cancers had increased percentages of CD8+ TILs (cytotoxic T cells) as compared to individuals with MSS colon cancer (47.3 vs. 24.04% of the infiltrate CD8+, respectively). No differences in the levels of CD25+ T cells were observed between individuals with MSI-H colon cancers and MSS colon cancers (0.53 vs. 0.54% CD25+, respectively). Together, these data suggest that the survival advantage enjoyed by patients with MSI-H colorectal cancer may, in part, be attributed to the increased cytolytic response, but not to an antigen-specific immunosuppressive response in MSS patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19165625     DOI: 10.1007/s10689-009-9233-0

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  81 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

3.  Characterization of activated lymphocytes in colon cancer.

Authors:  E C Ebert; R E Brolin; A I Roberts
Journal:  Clin Immunol Immunopathol       Date:  1989-01

4.  CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells.

Authors:  E Suri-Payer; A Z Amar; A M Thornton; E M Shevach
Journal:  J Immunol       Date:  1998-02-01       Impact factor: 5.422

Review 5.  New aspects in molecular diagnosis of Lynch syndrome (HNPCC).

Authors:  Ivana Fridrichova
Journal:  Cancer Biomark       Date:  2006       Impact factor: 4.388

6.  High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability.

Authors:  R Dolcetti; A Viel; C Doglioni; A Russo; M Guidoboni; E Capozzi; N Vecchiato; E Macrì; M Fornasarig; M Boiocchi
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

7.  Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients.

Authors:  Rebecca P Petersen; Michael J Campa; Justin Sperlazza; Debbi Conlon; Mary-Beth Joshi; David H Harpole; Edward F Patz
Journal:  Cancer       Date:  2006-12-15       Impact factor: 6.860

8.  Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation.

Authors:  Edward Y Woo; Heidi Yeh; Christina S Chu; Katia Schlienger; Richard G Carroll; James L Riley; Larry R Kaiser; Carl H June
Journal:  J Immunol       Date:  2002-05-01       Impact factor: 5.422

9.  Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer.

Authors:  Sebastian Hinz; Laia Pagerols-Raluy; Hans-Heinrich Oberg; Ole Ammerpohl; Sandra Grüssel; Bence Sipos; Robert Grützmann; Christian Pilarsky; Hendrik Ungefroren; Hans-Detlev Saeger; Günter Klöppel; Dieter Kabelitz; Holger Kalthoff
Journal:  Cancer Res       Date:  2007-09-01       Impact factor: 12.701

10.  Selective depletion of Foxp3+ regulatory T cells induces a scurfy-like disease.

Authors:  Katharina Lahl; Christoph Loddenkemper; Cathy Drouin; Jennifer Freyer; Jon Arnason; Gérard Eberl; Alf Hamann; Hermann Wagner; Jochen Huehn; Tim Sparwasser
Journal:  J Exp Med       Date:  2007-01-02       Impact factor: 14.307

View more
  25 in total

1.  Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI.

Authors:  Vanessa Deschoolmeester; Marc Baay; Filip Lardon; Patrick Pauwels; Marc Peeters
Journal:  Cancer Microenviron       Date:  2011-05-27

2.  Novel Proteome Extraction Method Illustrates a Conserved Immunological Signature of MSI-H Colorectal Tumors.

Authors:  Elez D Vainer; Juliane Kania-Almog; Ghadeer Zatara; Yishai Levin; Gilad W Vainer
Journal:  Mol Cell Proteomics       Date:  2020-07-08       Impact factor: 5.911

3.  Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  D Scott McMeekin; David L Tritchler; David E Cohn; David G Mutch; Heather A Lankes; Melissa A Geller; Matthew A Powell; Floor J Backes; Lisa M Landrum; Richard Zaino; Russell D Broaddus; Nilsa Ramirez; Feng Gao; Shamshad Ali; Kathleen M Darcy; Michael L Pearl; Paul A DiSilvestro; Shashikant B Lele; Paul J Goodfellow
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

Review 4.  A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.

Authors:  Vanessa Deschoolmeester; Marc Baay; Pol Specenier; Filip Lardon; Jan B Vermorken
Journal:  Oncologist       Date:  2010-06-28

5.  Tumor-Infiltrating Lymphocytes, Crohn's-Like Lymphoid Reaction, and Survival From Colorectal Cancer.

Authors:  Laura S Rozek; Stephanie L Schmit; Joel K Greenson; Lynn P Tomsho; Hedy S Rennert; Gad Rennert; Stephen B Gruber
Journal:  J Natl Cancer Inst       Date:  2016-05-12       Impact factor: 13.506

6.  Invasive front of colorectal cancer: dynamic interface of pro-/anti-tumor factors.

Authors:  Inti Zlobec; Alessandro Lugli
Journal:  World J Gastroenterol       Date:  2009-12-21       Impact factor: 5.742

Review 7.  Clinical implications of microsatellite instability in sporadic colon cancers.

Authors:  Frank A Sinicrope; Daniel J Sargent
Journal:  Curr Opin Oncol       Date:  2009-07       Impact factor: 3.645

8.  Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients.

Authors:  Vanessa Deschoolmeester; Marc Baay; Eric Van Marck; Joost Weyler; Peter Vermeulen; Filip Lardon; Jan B Vermorken
Journal:  BMC Immunol       Date:  2010-04-12       Impact factor: 3.615

Review 9.  Current hypotheses on how microsatellite instability leads to enhanced survival of Lynch Syndrome patients.

Authors:  Kristen M Drescher; Poonam Sharma; Henry T Lynch
Journal:  Clin Dev Immunol       Date:  2010-06-10

10.  Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.

Authors:  Patrick G Gavin; Linda H Colangelo; Debora Fumagalli; Noriko Tanaka; Matthew Y Remillard; Greg Yothers; Chungyeul Kim; Yusuke Taniyama; Seung Il Kim; Hyun Joo Choi; Nicole L Blackmon; Corey Lipchik; Nicholas J Petrelli; Michael J O'Connell; Norman Wolmark; Soonmyung Paik; Kay L Pogue-Geile
Journal:  Clin Cancer Res       Date:  2012-10-08       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.